BC
BLUE

Bridgefront Capital’s bluebird bio BLUE Stock Holding History

Bridgefront Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,337
Closed -$85K – 463
2023
Q1 		$85K Buy
+1,337
New +$153K 0.05% 398
2021
Q3 		– Sell
-953
Closed -$395K – 354
2021
Q2 		$395K Sell
953
-647
-40% -$256K 0.15% 243
2021
Q1 		$625K Buy
+1,600
New +$788K 0.19% 156

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bridgefront Capital's BLUE Position: Q2 2023 in Review

Bridgefront Capital sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 1,337 shares — an estimated $85K sold.

Bridgefront Capital first reported a position in BLUE in Q1 2021 and held it in 3 quarters. The position peaked at $625K in Q1 2021. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

  • Bridgefront Capital reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
  • Bridgefront Capital sold 1,337 bluebird bio shares in Q2 2023, an estimated $85K.
  • Bridgefront Capital first reported a position in bluebird bio in Q1 2021 and held it in 3 quarters.
  • Bridgefront Capital's bluebird bio position peaked at $625K in Q1 2021.
  • 175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on Bridgefront Capital's 13F filing for Q2 2023, filed 14 Aug 2023.